Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|4|368-383

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.4, 2010-06, pp. : 368-383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New inhibitors of poly(ADP-ribose) polymerase (PARP)

By Peukert Stefan   Schwahn Uwe  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 11, 2004-11 ,pp. : 1531-1551

Informa Healthcare

Access to resources Recommend Favorite

Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 4, 2011-12 ,pp. : 326-333

Bentham Science Publishers

Access to resources Recommend Favorite

Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, Member 14 (PARP14)

By  

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 19, 2018-11 ,pp. : 1659-1669

Bentham Science Publishers

Access to resources Recommend Favorite

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

By  

Clinical Cancer Drugs, Vol. 1, Iss. 2, 2014-01 ,pp. : 127-148

Bentham Science Publishers

Access to resources Recommend Favorite

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

By  

Clinical Cancer Drugs, Vol. 1, Iss. 2, 2014-05 ,pp. : 127-148

Bentham Science Publishers

Access to resources Recommend Favorite